Re-administration of pembrolizumab with prednisolone after pembrolizumab-induced nephrotic syndrome
Immune checkpoint inhibitors (ICIs) are associated with a unique spectrum of immune-related adverse events (irAEs) that are different from those occurring after conventional chemotherapy. Despite the risk of irAE recurrence, re-administration of ICIs after high-grade irAEs is critical, when considering their potential clinical benefits. Here, we report the first known case wherein pembrolizumab, an anti –programmed death 1 (PD-1) monoclonal antibody, was successfully re-administered with corticosteroids in a patient with severe nephrotic syndrome (NS) that developed during pembrolizumab therapy.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Susumu Saito, Tsukasa Kadota, Mina Gochi, Masamichi Takagi, Kazuyoshi Kuwano Tags: Letter to the Editor Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Corticosteroid Therapy | Nephrotic Syndrome | Prednisolone